Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 906 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Saline Infusion Clear all
Completed Early Phase 1 Interventional

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

NCT05291286
View directory record Official record
Conditions
Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19

NCT04583969
View directory record Official record
Conditions
COVID-19
Interventions
Lenzilumab, Placebo, Remdesivir
Biological · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
53
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

NCT04600089
View directory record Official record
Conditions
Descending Aortic Dissection, Postoperative Pain, Thoracoabdominal Aortic Aneurysm
Interventions
Saline, Ketamine
Drug
Lead sponsor
Eric Johnson
Other
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

This is a Study to Determine the Antidepressant Effects of AZD6765

NCT00986479
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
AZD6765, Placebo to AZD6765
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 14, 2026, 2:57 PM EDT
Terminated Phase 4 Interventional Results available

Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia

NCT04140396
View directory record Official record
Conditions
Rib Fractures
Interventions
Saline infusion, Lidocaine infusion
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 14, 2026, 2:57 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation

NCT03610282
View directory record Official record
Conditions
Anesthesia
Interventions
IV Methylphenidate, Propofol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 3 Interventional

Global Study of Del-desiran for the Treatment of DM1

NCT06411288
View directory record Official record
Conditions
DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Steinert, Myotonic Muscular Dystrophy
Interventions
AOC 1001 (del-desiran), Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
18
States / cities
Stanford, California • Denver, Colorado • Gainesville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 14, 2026, 2:57 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness

NCT01844726
View directory record Official record
Conditions
Psychiatric Illness, Healthy
Interventions
GLYX-13, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 40 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

NCT01147640
View directory record Official record
Conditions
Complicated Intra-abdominal Infection
Interventions
CXA-101/ tazobactam and metronidazole, meropenem plus saline placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Orange, California • Torrance, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

NCT02165332
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 14, 2026, 2:57 PM EDT
Not yet recruiting Not applicable Interventional

Impact of Intravenous Caffeine on Atrial Electrical Properties and Potential Arrythmia Induction

NCT05464940
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Intravenous caffeine, Masked Placebo
Other
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
21 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Loma Linda, California • Overland Park, Kansas • Independence, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 14, 2026, 2:57 PM EDT
Recruiting Phase 3 Interventional

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

NCT06679855
View directory record Official record
Conditions
Post-ligation Cardiac Syndrome
Interventions
Milrinone infusion, Placebo infusion
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 3 Months
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

NCT00604214
View directory record Official record
Conditions
Sepsis
Interventions
Drotrecogin alfa (activated), Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
23
States / cities
Birmingham, Alabama • Loma Linda, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 14, 2026, 2:57 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

NCT04547140
View directory record Official record
Conditions
COVID-19
Interventions
Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 14, 2026, 2:57 PM EDT
Recruiting Phase 3 Interventional

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

NCT07220915
View directory record Official record
Conditions
Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Interventions
Panzyga, 10% Intravenous Solution, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Glendale, Arizona • Mesa, Arizona • Scottsdale, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 14, 2026, 2:57 PM EDT
Terminated Phase 2 Interventional Results available

The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients

NCT00791076
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo, Pancreatic Polypeptide (PP)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection

NCT02160808
View directory record Official record
Conditions
Injury of Body of Pancreas
Interventions
Secretin, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study of CD101 IV in Healthy Subjects

NCT02516904
View directory record Official record
Conditions
Healthy
Interventions
CD101 IV, Placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001

NCT02563938
View directory record Official record
Conditions
Atopy
Interventions
AK001, Placebo
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 14, 2026, 2:57 PM EDT
Terminated Phase 3 Interventional Results available

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

NCT02626455
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia

NCT05047211
View directory record Official record
Conditions
Anemia, Iron Deficiency, Delivery Complication
Interventions
Ferrous sulfate, Iron dextran
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 14, 2026, 2:57 PM EDT
Active, not recruiting Phase 2 Interventional

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

NCT03478215
View directory record Official record
Conditions
Renal Transplantation, Mesenchymal Stem Cells
Interventions
Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 14, 2026, 2:57 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

NCT01951716
View directory record Official record
Conditions
Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions
Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 14, 2026, 2:57 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of IV Acetaminophen for Pain Management

NCT02028715
View directory record Official record
Conditions
Post-operative Pain
Interventions
Placebo, IV acetaminophen
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 14, 2026, 2:57 PM EDT